Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate

S. D. Williams, E. Velez-Garcia, I. Essessee, G. Ratkin, R. Birch, Lawrence Einhorn

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

One hundred ninety-one patients with recurrent or metastatic squamous cell carcinoma of head and neck origin were allocated at random to chemotherapy with conventional-dose weekly intravenous methotrexate or the combination of cisplatin, vinblastine, and bleomycin. Methotrexate induced responses in 16 of 98 patients (16%), whereas 22 of 92 (24%) responded to the combination regimen (P = not significant). Remission duration (20.2 weeks methotrexate; 15.1 weeks combination) was similar on both arms, as was survival (31.4 weeks methotrexate; 29.0 weeks combination). Therapy was relatively well-tolerated on both treatment arms, although methotrexate produced more mucositis and the combination more gastrointestinal and renal toxicity. Response to chemotherapy and disease confined to the locoregional area were associated with somewhat longer survival. Combination chemotherapy as given in this study did not improve any observed parameter, and the results of treatment were poor in both arms.

Original languageEnglish (US)
Pages (from-to)18-23
Number of pages6
JournalCancer
Volume57
Issue number1
DOIs
StatePublished - 1986

Fingerprint

Vinblastine
Bleomycin
Head and Neck Neoplasms
Methotrexate
Cisplatin
Drug Therapy
Mucositis
Survival
Combination Drug Therapy
Therapeutics
Kidney

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate. / Williams, S. D.; Velez-Garcia, E.; Essessee, I.; Ratkin, G.; Birch, R.; Einhorn, Lawrence.

In: Cancer, Vol. 57, No. 1, 1986, p. 18-23.

Research output: Contribution to journalArticle

Williams, S. D. ; Velez-Garcia, E. ; Essessee, I. ; Ratkin, G. ; Birch, R. ; Einhorn, Lawrence. / Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate. In: Cancer. 1986 ; Vol. 57, No. 1. pp. 18-23.
@article{b42c462359994818a2528d9388efa6cc,
title = "Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate",
abstract = "One hundred ninety-one patients with recurrent or metastatic squamous cell carcinoma of head and neck origin were allocated at random to chemotherapy with conventional-dose weekly intravenous methotrexate or the combination of cisplatin, vinblastine, and bleomycin. Methotrexate induced responses in 16 of 98 patients (16{\%}), whereas 22 of 92 (24{\%}) responded to the combination regimen (P = not significant). Remission duration (20.2 weeks methotrexate; 15.1 weeks combination) was similar on both arms, as was survival (31.4 weeks methotrexate; 29.0 weeks combination). Therapy was relatively well-tolerated on both treatment arms, although methotrexate produced more mucositis and the combination more gastrointestinal and renal toxicity. Response to chemotherapy and disease confined to the locoregional area were associated with somewhat longer survival. Combination chemotherapy as given in this study did not improve any observed parameter, and the results of treatment were poor in both arms.",
author = "Williams, {S. D.} and E. Velez-Garcia and I. Essessee and G. Ratkin and R. Birch and Lawrence Einhorn",
year = "1986",
doi = "10.1002/1097-0142(19860101)57:1<18::AID-CNCR2820570106>3.0.CO;2-V",
language = "English (US)",
volume = "57",
pages = "18--23",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate

AU - Williams, S. D.

AU - Velez-Garcia, E.

AU - Essessee, I.

AU - Ratkin, G.

AU - Birch, R.

AU - Einhorn, Lawrence

PY - 1986

Y1 - 1986

N2 - One hundred ninety-one patients with recurrent or metastatic squamous cell carcinoma of head and neck origin were allocated at random to chemotherapy with conventional-dose weekly intravenous methotrexate or the combination of cisplatin, vinblastine, and bleomycin. Methotrexate induced responses in 16 of 98 patients (16%), whereas 22 of 92 (24%) responded to the combination regimen (P = not significant). Remission duration (20.2 weeks methotrexate; 15.1 weeks combination) was similar on both arms, as was survival (31.4 weeks methotrexate; 29.0 weeks combination). Therapy was relatively well-tolerated on both treatment arms, although methotrexate produced more mucositis and the combination more gastrointestinal and renal toxicity. Response to chemotherapy and disease confined to the locoregional area were associated with somewhat longer survival. Combination chemotherapy as given in this study did not improve any observed parameter, and the results of treatment were poor in both arms.

AB - One hundred ninety-one patients with recurrent or metastatic squamous cell carcinoma of head and neck origin were allocated at random to chemotherapy with conventional-dose weekly intravenous methotrexate or the combination of cisplatin, vinblastine, and bleomycin. Methotrexate induced responses in 16 of 98 patients (16%), whereas 22 of 92 (24%) responded to the combination regimen (P = not significant). Remission duration (20.2 weeks methotrexate; 15.1 weeks combination) was similar on both arms, as was survival (31.4 weeks methotrexate; 29.0 weeks combination). Therapy was relatively well-tolerated on both treatment arms, although methotrexate produced more mucositis and the combination more gastrointestinal and renal toxicity. Response to chemotherapy and disease confined to the locoregional area were associated with somewhat longer survival. Combination chemotherapy as given in this study did not improve any observed parameter, and the results of treatment were poor in both arms.

UR - http://www.scopus.com/inward/record.url?scp=0022643589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022643589&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19860101)57:1<18::AID-CNCR2820570106>3.0.CO;2-V

DO - 10.1002/1097-0142(19860101)57:1<18::AID-CNCR2820570106>3.0.CO;2-V

M3 - Article

C2 - 2416423

AN - SCOPUS:0022643589

VL - 57

SP - 18

EP - 23

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -